My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 104

    1.

    Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.

    Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC.

    Diabetes Care. 2004 Nov;27(11):2577-80.PMID: 15504988 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.

    Keidar S, Guttmann H, Stam T, Fishman I, Shapira C.

    Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1192-4.PMID: 17636555 [PubMed - indexed for MEDLINE]Related articles

    3.

    Lipoprotein effects of different thiazolidinediones in clinical practice.

    Ovalle F, Bell DS.

    Endocr Pract. 2002 Nov-Dec;8(6):406-10.PMID: 15251829 [PubMed - indexed for MEDLINE]Related articles

    4.

    Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.

    Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S.

    Diabet Med. 2007 Jan;24(1):94-7.PMID: 17227331 [PubMed - indexed for MEDLINE]Related articles

    5.

    Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.

    Gutschi LM, Malcolm JC, Favreau CM, Ooi TC.

    Ann Pharmacother. 2006 Sep;40(9):1672-6. Epub 2006 Aug 15.PMID: 16912247 [PubMed - indexed for MEDLINE]Related articles

    6.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    7.

    A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

    Hanefeld M, Patwardhan R, Jones NP; Rosiglitazone Clinical Trials Study Group.

    Nutr Metab Cardiovasc Dis. 2007 Jan;17(1):13-23. Epub 2006 Mar 20.PMID: 17174222 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    9.

    A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

    Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators.

    Diabetes Care. 2005 Jul;28(7):1547-54.PMID: 15983299 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    11.

    Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

    Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group.

    J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76. Erratum in: J Clin Endocrinol Metab. 2005 Feb;90(2):746. PMID: 15579760 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

    Seber S, Ucak S, Basat O, Altuntas Y.

    Diabetes Res Clin Pract. 2006 Jan;71(1):52-8. Epub 2005 Jul 11.PMID: 16009445 [PubMed - indexed for MEDLINE]Related articles

    13.

    Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.

    Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T.

    Circulation. 2008 Apr 22;117(16):2123-30. Epub 2008 Apr 14.PMID: 18413496 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial.

    Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC.

    Adv Ther. 2006 Sep-Oct;23(5):799-808.PMID: 17142216 [PubMed - indexed for MEDLINE]Related articles

    15.

    The long-term effects of rosiglitazone on serum lipid concentrations and body weight.

    Shim WS, Do MY, Kim SK, Kim HJ, Hur KY, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS.

    Clin Endocrinol (Oxf). 2006 Oct;65(4):453-9.PMID: 16984237 [PubMed - indexed for MEDLINE]Related articles

    16.

    Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.

    Orbay E, Sargin M, Sargin H, Gözü H, Bayramiçli OU, Yayla A.

    Endocr J. 2004 Dec;51(6):521-7.PMID: 15644569 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

    Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.

    Diabetes Care. 2007 Feb;30(2):217-23. Erratum in: Diabetes Care. 2007 May;30(5):1330. PMID: 17259484 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.

    Osei K, Gaillard T, Cook C, Kaplow J, Bullock M, Schuster D.

    Ethn Dis. 2005 Autumn;15(4):641-8.PMID: 16259488 [PubMed - indexed for MEDLINE]Related articles

    19.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.

    Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND.

    J Diabetes Complications. 2007 Mar-Apr;21(2):118-23.PMID: 17331860 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity